Cargando…
Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: H...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537937/ https://www.ncbi.nlm.nih.gov/pubmed/34684054 http://dx.doi.org/10.3390/medicina57101017 |
_version_ | 1784588387688120320 |
---|---|
author | Bertoli, Federica Bais, Bruno De Silvestri, Daniele Mariotti, Barbara Veritti, Daniele Cavarape, Alessandro Catena, Cristiana Lanzetta, Paolo Sechi, Leonardo Alberto Colussi, GianLuca |
author_facet | Bertoli, Federica Bais, Bruno De Silvestri, Daniele Mariotti, Barbara Veritti, Daniele Cavarape, Alessandro Catena, Cristiana Lanzetta, Paolo Sechi, Leonardo Alberto Colussi, GianLuca |
author_sort | Bertoli, Federica |
collection | PubMed |
description | Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: Hypertensive patients with RVO were consecutively selected from 2008 to 2012 and followed for a median of 8.7 years. Ophthalmologists evaluated and treated RVO complications, and best-corrected visual acuity (BCVA) was checked at each visit during the first one year of follow-up. Survival analysis was conducted on the rate of the composite endpoint of all-cause deaths or non-fatal cardiovascular events. Results: Retrospectively, we collected data from 80 patients (age 68 ± 12 years, 39 males). Central and branch RVO was present in 41 and 39 patients, respectively, and 56 patients started ATAs (50 antiplatelet drugs, 6 warfarin, and 2 low-molecular weight heparin). Average BCVA of the cohort did not change significantly during one-year of follow-up. The only predictor of BCVA was the baseline BCVA value. There was a reduction in proportion and severity of macular edema and an increase in the cumulative proportion of retinal vein patency reestablishment during the follow-up, independent of treatment. ATAs had no effects on one-year BCVA, intraocular complications, or the composite endpoint rate. Conclusions: In this exploratory study, ATAs had no effect on BCVA during the first one year of follow-up and on the composite endpoint during the long-term follow-up. Further prospective studies need to be conducted with an accurate standardization of the intraocular and antithrombotic treatment to define the positive or negative role of ATAs in hypertensive patients with RVO. |
format | Online Article Text |
id | pubmed-8537937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85379372021-10-24 Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study Bertoli, Federica Bais, Bruno De Silvestri, Daniele Mariotti, Barbara Veritti, Daniele Cavarape, Alessandro Catena, Cristiana Lanzetta, Paolo Sechi, Leonardo Alberto Colussi, GianLuca Medicina (Kaunas) Article Background and objectives: Because few data are available, the aim of this study is to analyze the effects of antithrombotic agents (ATAs) on visual function and long-term risk of cardiovascular events and mortality in hypertensive patients with retinal vein occlusion (RVO). Materials and methods: Hypertensive patients with RVO were consecutively selected from 2008 to 2012 and followed for a median of 8.7 years. Ophthalmologists evaluated and treated RVO complications, and best-corrected visual acuity (BCVA) was checked at each visit during the first one year of follow-up. Survival analysis was conducted on the rate of the composite endpoint of all-cause deaths or non-fatal cardiovascular events. Results: Retrospectively, we collected data from 80 patients (age 68 ± 12 years, 39 males). Central and branch RVO was present in 41 and 39 patients, respectively, and 56 patients started ATAs (50 antiplatelet drugs, 6 warfarin, and 2 low-molecular weight heparin). Average BCVA of the cohort did not change significantly during one-year of follow-up. The only predictor of BCVA was the baseline BCVA value. There was a reduction in proportion and severity of macular edema and an increase in the cumulative proportion of retinal vein patency reestablishment during the follow-up, independent of treatment. ATAs had no effects on one-year BCVA, intraocular complications, or the composite endpoint rate. Conclusions: In this exploratory study, ATAs had no effect on BCVA during the first one year of follow-up and on the composite endpoint during the long-term follow-up. Further prospective studies need to be conducted with an accurate standardization of the intraocular and antithrombotic treatment to define the positive or negative role of ATAs in hypertensive patients with RVO. MDPI 2021-09-25 /pmc/articles/PMC8537937/ /pubmed/34684054 http://dx.doi.org/10.3390/medicina57101017 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bertoli, Federica Bais, Bruno De Silvestri, Daniele Mariotti, Barbara Veritti, Daniele Cavarape, Alessandro Catena, Cristiana Lanzetta, Paolo Sechi, Leonardo Alberto Colussi, GianLuca Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title | Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title_full | Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title_fullStr | Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title_full_unstemmed | Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title_short | Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study |
title_sort | effects of antithrombotic agents on ophthalmological outcomes, cardiovascular risk, and mortality in hypertensive patients with retinal vein occlusion: an exploratory retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537937/ https://www.ncbi.nlm.nih.gov/pubmed/34684054 http://dx.doi.org/10.3390/medicina57101017 |
work_keys_str_mv | AT bertolifederica effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT baisbruno effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT desilvestridaniele effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT mariottibarbara effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT verittidaniele effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT cavarapealessandro effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT catenacristiana effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT lanzettapaolo effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT sechileonardoalberto effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy AT colussigianluca effectsofantithromboticagentsonophthalmologicaloutcomescardiovascularriskandmortalityinhypertensivepatientswithretinalveinocclusionanexploratoryretrospectivestudy |